Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 5/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25532034 | 0.78 | GAA (0.45) | MAPTGAAALDH1A1MGAMSI | |
| SCHEMBL1034918 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2EGLN1MAPTGAATDP1 | |
| SCHEMBL29090603 | 0.74 | EGLN1 (0.46) | SMN1; SMN2EGLN1MAPTGAATDP1 | |
| SCHEMBL24424298 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2EGLN1MAPTGAATDP1 | |
| SCHEMBL6016763 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2EGLN1 | |
| SCHEMBL27490039 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2EGLN1 | |
| SCHEMBL22702628 | 0.71 | SMN1; SMN2 (0.44) | SMN1; SMN2EGLN1MAPTGAATDP1 | |
| SCHEMBL22693768 | 0.71 | SMN1; SMN2 (0.44) | SMN1; SMN2EGLN1MAPTGAATDP1 | |
| SCHEMBL6016802 | 0.71 | SMN1; SMN2 (0.50) | SMN1; SMN2EGLN1MAPTGAATDP1 | |
| SCHEMBL6016803 | 0.71 | SMN1; SMN2 (0.50) | SMN1; SMN2EGLN1MAPTGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | SMN1; SMN2 1368/4885EGLN1 3779/4885MAPT 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.